Loading...
Market
Will Bristol Myers Squibb make another investment in Evotec by the end of 2024?
3
Resolution / Starting Odds
Yes • 50%
No • 50%
Official press releases from Bristol Myers Squibb or Evotec
Story
Evotec and Bristol Myers Squibb Expand Proteomics Partnership with $50 Million Upfront
Oct 23, 2024, 06:02 AM
Evotec SE and Bristol Myers Squibb have announced an expansion of their proteomics partnership, which will now include a new molecular glue-based collaboration. This collaboration begins with a $50 million upfront payment from Bristol Myers Squibb to Evotec. The partnership aims to build a molecular glue-based pipeline, leveraging the success of previous deals between the two companies. The new collaboration focuses on non-protac degraders.
View original story
Similar markets
Yes • 50%
No • 50%
Roche • 25%
Novartis • 25%
Sanofi • 25%
No counteroffer • 25%
Takeover completed • 25%
Takeover offer made but not completed • 25%
No takeover offer made • 25%
Triton sells its stake • 25%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Successful acquisition at €11 per share • 25%
Acquisition at a different price • 25%
Acquisition fails • 25%
Acquisition postponed • 25%
Major success • 25%
Moderate success • 25%
Limited success • 25%
Failure • 25%